CD93 has been verified as a crucial regulator in modulating abnormal angiogenesis, vascular function, cytoskeleton orchestrating, ECM organization and glucometabolic regulation in GBM (Langenkamp et al. 2015; Lugano et al. 2018; Strawbridge et al. 2016). This evidence concerns the gene CD93 and glioblastoma.